Bortezomib compositions
AssigneeMaia Pharmaceuticals, Inc.
InventorsSrikanth SUNDARAM, Daniel Charles STEWART
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to ready-to-use liquid aqueous bortezomib compositions bortezomib and pharmaceutical excipients. Other aspects include methods of preparing such ready-to-use liquid aqueous bortezomib compositions, and methods of using such ready-to-use liquid bortezomib compositions in therapeutic applications.
Claims8
1-77. (canceled)
A liquid, ready-to-use aqueous composition consisting of about 1 mg/mL bortezomib, about 10 mg/mL mannitol, about 20 mg/mL dimethyl sulfoxide, about 0.82 mg/mL sodium acetate, water and, optionally, hydrochloric acid, sodium hydroxide, or a combination thereof, wherein the pH of the ready-to-use composition is about 5 to about 6.
A liquid, ready-to-use aqueous composition consisting of about 2.5 mg/mL bortezomib, about 25 mg/mL mannitol, about 22 mg/mL dimethyl sulfoxide, about 0.82 mg/mL sodium acetate, water and, optionally, hydrochloric acid, sodium hydroxide, or a combination thereof, wherein the pH of the ready-to-use composition is about 5 to about 6.
A liquid, ready-to-use aqueous composition consisting of bortezomib, mannitol, dimethyl sulfoxide, sodium acetate, water and, optionally, hydrochloric acid, sodium hydroxide, or a combination thereof, wherein (i) the pH of the ready-to-use composition is about 5 to about 6 and (ii) after storage at 2-8° C. for 12 months, at least 90% of the bortezomib remains in the composition.
Dependencies are inferred from the claim text.